Baseimmune key facts
- Developer of a platform designed for pathogen analysis to create antigen and vaccine designs.
- It has raised $16.8M; the latest was Accelerator/Incubator in May 2024.
- Notable investors include Tiny Supercomputer Investment Company, Cherry Ventures, IQ Capital Partners, Hoxton Ventures, MSD Global Health Innovation Fund — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Baseimmune
15+- ·The complete investor list: 15 names
- ·Watch Baseimmune: the Monday email on marks, rounds and moves
Baseimmune funding rounds
No funding rounds for Baseimmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Baseimmune investors
15 investors are on record for Baseimmune, including Tiny Supercomputer Investment Company, Cherry Ventures, IQ Capital Partners and Hoxton Ventures. By type, the record holds 5 venture capital firms.
About Baseimmune
Developer of a platform designed for pathogen analysis to create antigen and vaccine designs. The company's platform is based on a technology that can generate antigens using a level of informatics depth to tackle emerging and challenging pathogens, enabling healthcare providers to ensure the vaccines remain effective even if a pathogen mutates.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 28
- Website
- baseimmune.co.uk/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Baseimmune doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.